Výsledky vyhledávání - "Warfarin/adverse effects"

Akademický článek

Wunderlich Syndrome in a Peritoneal Dialysis Patient with Warfarin Iatrogenic Coagulopathy: Should We Really be so Aggressive on Cardioembolic Events Prevention?

Autor: Juliana Carneiro, João Grilo, Joana Coutinho, Raquel Chorão, Ernesto Rocha

Publikováno v: Revista Portuguesa de Nefrologia e Hipertensão, Vol 37, Iss 2, Pp 106-111 (2023)

Wunderlich syndrome is a rare condition characterized by atraumatic spontaneous renal hemorrhage that can have serious associated complications, especially in chronic kidney disease and end-stage kidney disease patients due to their complexity. Diag

Externí odkaz: https://doaj.org/article/b61f264fca514820ae59f378dc7a16c7

Zobrazit plný text záznamu

Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre

Autor: Petra Bistrovic, Anica Sabljic, Ivona Kovacevic, Tomislav Cikara, Tatjana Keres, Tomo Lucijanic, Josko Mitrovic, Diana Delic-Brkljacic, Sime Manola, Marko Lucijanic

Introduction: There are conflicting data on prior oral-anticoagulant (OAC) use and outcomes of hospitalized COVID-19 patients. Due to uncertainties regarding associated risks with the prior OAC use, we have investigated this issue in a large cohort o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b438a24431e8fa1d030b453774d4df6
https://doi.org/10.1016/j.ijcard.2022.11.051

Zobrazit plný text záznamu

Drug Interactions Affecting Oral Anticoagulant Use

Autor: Mar, Philip L., Gopinathannair, Rakesh, Gengler, Brooke E., Chung, Mina K., Perez, Arturo, Dukes, Jonathan, Ezekowitz, Michael D., Lakkireddy, Dhanunjaya, Lip, Gregory Y. H., Miletello, Mike, Noseworthy, Peter A., Reiffel, James, Tisdale, James E., Olshansky, Brian

Publikováno v: Mar, P L, Gopinathannair, R, Gengler, B E, Chung, M K, Perez, A, Dukes, J, Ezekowitz, M D, Lakkireddy, D, Lip, G Y H, Miletello, M, Noseworthy, P A, Reiffel, J, Tisdale, J E, Olshansky, B & from the American Heart Association Electrocardiography & Arrhythmias Committee of the Council of Clinical Cardiology 2022, ' Drug Interactions Affecting Oral Anticoagulant Use ', Circulation. Arrhythmia and Electrophysiology, vol. 15, no. 6, e007956 . https://doi.org/10.1161/CIRCEP.121.007956
Circ Arrhythm Electrophysiol

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are an important ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba4a782ac6b084be29f09514067cc99b
https://doi.org/10.1161/circep.121.007956

Zobrazit plný text záznamu

A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease

Autor: Kathrine Parker, John Hartemink, Ananya Saha, Roshni Mitra, Penny Lewis, Albert Power, Satarupa Choudhuri, Sandip Mitra, Jecko Thachil

Publikováno v: Parker, K, Hartemink, J, Saha, A, Mitra, R, Lewis, P, Power, A, Choudhuri, S, Mitra, S & Thachil, J 2022, ' A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease ', Journal of Nephrology . https://doi.org/10.1007/s40620-022-01413-x
Parker, K, Hartemink, J, Saha, A, Mitra, R, Lewis, P, Power, A, Choudhuri, S, Mitra, S & Thachil, J 2022, ' A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease ', Journal of Nephrology, vol. 35, no. 8, pp. 2015-2033 . https://doi.org/10.1007/s40620-022-01413-x

BackgroundPatients with chronic kidney disease (CKD) have an increased risk of venous thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulants have not been studied in randomised controlled trials with CrCl MethodsWe conducted a systematic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904cfee5ca9e03a8e242c35bdc9dc982
http://www.scopus.com/inward/record.url?scp=85137019706&partnerID=8YFLogxK

Zobrazit plný text záznamu

Akademický článek

Warfarin: pharmacological profile and drug interactions with antidepressants

Autor: Juliana Souto Teles, Ellen Yukie Fukuda, David Feder

Publikováno v: Einstein (São Paulo), Vol 10, Iss 1, Pp 110-115 (2012)

Oral anticoagulants are among the drugs with the greatest numberof drug interactions. The concomitant use of several medications isa common practice in patients with cardiovascular problems, whooften also present with depression; therefore, the proba

Externí odkaz: https://doaj.org/article/66579e14feb842dd91c1e3fb0cb047b2

Zobrazit plný text záznamu

All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System

Autor: Stefan Agewall, Jesper K. Jensen, Thomas G. von Lueder, Ingrid Hopper, Dipak Kotecha, Dan Atar, Moo Hyun Kim, Victor L. Serebruany, Robert J. Mentz

Publikováno v: von Lueder, T G, Atar, D, Agewall, S, Jensen, J K, Hopper, I, Kotecha, D, Mentz, R J, Kim, M H & Serebruany, V L 2019, ' All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System ', American Journal of Therapeutics, vol. 26, no. 6, pp. e671-e678 . https://doi.org/10.1097/MJT.0000000000000883

BACKGROUND: Many patients with heart failure (HF) are treated with warfarin or non-vitamin K oral anticoagulants (NOACs). Randomized outcome-driven comparisons of different anticoagulant strategies in HF are lacking. Data from international, governme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b600a199dfd787497131ceec46f9df99
https://doi.org/10.1097/mjt.0000000000000883

Zobrazit plný text záznamu

Nefropatia Associada aos Anticoagulantes Orais: Uma Entidade a Reconhecer

Autor: Fortes, Pedro, Alves, Filipa, Silva, Cristina, Pessegueiro, Pedro

Publikováno v: Medicina Interna, Volume: 26, Issue: 1, Pages: 52-59, Published: MAR 2019

A nefropatia associada aos anticoagulantes orais (NAAO), da qual o paradigma é a nefropatia associada à varfarina, tem sido definida de modo variável na literatura, dificultando avaliações epidemiológicas e clínicas rigorosas. A maior parte do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1126318a4d3023fb5fab417b2bbed5f

Zobrazit plný text záznamu

The safety of NOACs in atrial fibrillation patient subgroups:A narrative review

Autor: Gregory Y.H. Lip

Publikováno v: Lip, G Y H 2019, ' The safety of NOACs in atrial fibrillation patient subgroups : A narrative review ', International Journal of Clinical Practice, vol. 73, no. 2, e13285 . https://doi.org/10.1111/ijcp.13285
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

AIM: Four non-vitamin K oral anticoagulants (NOACs) have been evaluated in clinical trials for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the NOACs have been shown to be at least non-inferior to warfarin for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31a03596faff0bfee86879256cde1c4
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf

Zobrazit plný text záznamu

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Autor: Johanne SILVAIN, Sotir Marchev, Frans Van de Werf, Juhani Airaksinen, Ru San Tan, Daniel Duerschmied, Bela Merkely, Rolf Wachter, Bassem A. Samad, Philippe Gabriel STEG, Dirk Westermann, Didier CARRIE, Fernando Lanas, MICHELE SENNI, José Ramón Rumoroso, Wanwarang Wongcharoen, Grzegorz Opolski, Niall Mahon, Sandro Brusich

Publikováno v: Cannon, C P, Bhatt, D L, Oldgren, J, Lip, G Y H, Ellis, S G, Maeng, M, Merkely, B, Manassie, J, Januzzi, J L, Ten Berg, J M, Steg, P G, Hohnloser, S H & RE-DUAL PCI Steering Committee and Investigators 2017, ' Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation ', The New England Journal of Medicine, vol. 377, no. 16, pp. 1513-1524 . https://doi.org/10.1056/NEJMoa1708454

BACKGROUND: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of blee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e13931000e1ba7b7512f50c0dfddb1d3
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-145511

Zobrazit plný text záznamu

POSTUPNICI ZA PERIPROCEDURALNO ZBRINJAVANJE I ZBRINJAVANJE KRVARENJA U BOLESNIKA LIJEČENIH NOVIM ORALNIM ANTIKOAGULANTNIM LIJEKOVIMA

Autor: Ivan Gornik, Ingrid Prkačin, Višnja Nesek Adam, Vlatko Grabovac, Vanja Giljača, Aljoša Šikić

Publikováno v: Liječnički vjesnik
Volume 139
Issue 3-4

Cilj terapije antagonistima vitamina K (varfarin) i novim oralnim antikoagulantnim lijekovima (NOAK-ima) jesu prevencija moždanog udara i drugih embolija kod bolesnika s nevalvularnom fibrilacijom atrija te liječenje i prevencija venske tromboembol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______951::feef038744f205769c0f02a6ffc6dcf0
https://hrcak.srce.hr/184329

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání